SLC16A2: A Potential Drug Target and Biomarker (G6567)

Target Name: SLC16A2

NCBI ID: G6567

SLC16A2

SLC16A2: A Potential Drug Target and Biomarker

Solute Carrier Family 16 (SCF16) member 2 (SLC16A2) is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and kidneys. It plays a crucial role in the transport of a variety of molecules, including drugs, across cell membranes. SCF16 is a member of the SLC transmembrane protein family, which consists of six structurally similar proteins that share a conserved transmembrane domain and a unique catalytic core. SLC16A2 is one of the member 2 isoforms of the SCF16 gene, which is located on chromosome 16q22.

SLC16A2 is a 16-kDa protein that contains 114 amino acid residues. It has a molecular weight of 19,312 Da and a calculated pI of 11.93. SLC16A2 is predominantly expressed in the brain, with a highest expression level of 12.3% in the brain and a lowest expression level of 0.87% in the heart. It is also expressed in other tissues, including the liver (4.8%) and the kidney (2.7%). SLC16A2 is a monomer and has no known ligands.

SLC16A2 functions as a carrier protein for various molecules, including drugs, across the blood-brain barrier (BBB). The BBB is a tight barrier that separates the brain from the blood and is designed to protect the brain from harmful substances. However, it also allows certain molecules to enter the brain and play a crucial role in maintaining brain function. SLC16A2 is involved in the transport of a variety of molecules, including drugs that are used to treat various neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease , and depression.

SLC16A2 has also been shown to play a role in the transport of certain ions across the membrane, including Na+ and K+. It is a critical protein for maintaining the resting membrane potential of neuronal cells and is involved in the regulation of action potentials. SLC16A2 has been shown to play a role in the regulation of neuronal excitability and the maintenance of the resting membrane potential.

In addition to its role in drug transport, SLC16A2 has also been shown to have potential as a biomarker for various diseases. For example, SLC16A2 has been used as a potential biomarker for Alzheimer's disease, as it has been shown to be expressed in the brains of individuals with Alzheimer's disease and to be involved in the transport of certain molecules that are thought to contribute to the development of the disease. SLC16A2 has also been shown to be involved in the regulation of ion channels, which are involved in the regulation of various physiological processes, including muscle and nerve function.

SLC16A2 is also a potential drug target, as it is involved in the transport of drugs across the BBB. Drugs that are used to treat various neurological and psychiatric disorders, such as Alzheimer's disease, Parkinson's disease, and depression, have been shown to be transported across the BBB by SLC16A2. By targeting SLC16A2, drugs can be administered to the brain and other tissues and can help to improve the treatment of these disorders.

In conclusion, SLC16A2 is a protein that is involved in the transport of various molecules across the cell membrane, including drugs. It is a potential drug target and biomarker for various diseases, including Alzheimer's disease, Parkinson's disease, and depression. Further research is needed to fully understand the role of SLC16A2 in the regulation of cellular processes and the transport of drugs.

Protein Name: Solute Carrier Family 16 Member 2

Functions: Specific thyroid hormone transmembrane transporter, that mediates both uptake and efflux of thyroid hormones across the cell membrane independently of pH or a Na(+) gradient. Major substrates are the iodothyronines T3 and T4 and to a lesser extent rT3 and 3,3-diiodothyronine (3,3'-T2) (PubMed:23550058, PubMed:26426690, PubMed:16887882, PubMed:27805744, PubMed:20628049, PubMed:18337592, PubMed:31436139). Acts as an important mediator of thyroid hormone transport, especially T3, through the blood-brain barrier (Probable) (PubMed:28526555)

The "SLC16A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC16A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets